| Dr Frank Fish, MD | |
|
200 Trenton Rd., Browns Mills, NJ 08015-1705 | |
| (609) 893-6611 | |
| (609) 735-1856 |
| Full Name | Dr Frank Fish |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 54 Years |
| Location | 200 Trenton Rd., Browns Mills, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265409817 | NPI | - | NPPES |
| 2040506 | Medicaid | NJ | |
| BNS056 | Other | OXFORD | |
| F01232 | Other | HEALTHNET | |
| 0004090785 | Other | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 25MA02749700 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Deborah Heart And Lung Center | Browns mills, NJ | Hospital |
| Capital Health Medical Center - Hopewell | Pennington, NJ | Hospital |
| Southern Ocean Medical Center | Manahawkin, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Professional Service Fund Of Deborah Heart And Lung Center | 4284537499 | 96 |
News Archive
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.
The University of Chicago Medicine Comer Children's Hospital has become the first in Illinois to offer pioneering, targeted, high-dose, intravenous radiation therapy for relapsed neuroblastoma and other difficult-to-treat cancers.
Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court for the Southern District of New York against Mylan Technologies Inc. ("Mylan") claiming infringement of certain Noven patents (the "Patents") by Mylan.
Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments have been approved for other forms of cancer.
Renal denervation leads to better outcomes than standard drug treatment in patients with advanced heart failure, according to research presented at ESC Congress 2012. The results of the Olomouc I pilot study were presented by Dr Miloš Táborský from the University Hospital Olomouc.
› Verified 4 days ago
| Entity Name | Professional Service Fund Of Deborah Heart & Lung Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407803596 PECOS PAC ID: 4284537499 Enrollment ID: O20040127000717 |
News Archive
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.
The University of Chicago Medicine Comer Children's Hospital has become the first in Illinois to offer pioneering, targeted, high-dose, intravenous radiation therapy for relapsed neuroblastoma and other difficult-to-treat cancers.
Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court for the Southern District of New York against Mylan Technologies Inc. ("Mylan") claiming infringement of certain Noven patents (the "Patents") by Mylan.
Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments have been approved for other forms of cancer.
Renal denervation leads to better outcomes than standard drug treatment in patients with advanced heart failure, according to research presented at ESC Congress 2012. The results of the Olomouc I pilot study were presented by Dr Miloš Táborský from the University Hospital Olomouc.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Frank Fish, MD 200 Trenton Rd., Browns Mills, NJ 08015-1705 Ph: (609) 893-6611 | Dr Frank Fish, MD 200 Trenton Rd., Browns Mills, NJ 08015-1705 Ph: (609) 893-6611 |
News Archive
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.
The University of Chicago Medicine Comer Children's Hospital has become the first in Illinois to offer pioneering, targeted, high-dose, intravenous radiation therapy for relapsed neuroblastoma and other difficult-to-treat cancers.
Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court for the Southern District of New York against Mylan Technologies Inc. ("Mylan") claiming infringement of certain Noven patents (the "Patents") by Mylan.
Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments have been approved for other forms of cancer.
Renal denervation leads to better outcomes than standard drug treatment in patients with advanced heart failure, according to research presented at ESC Congress 2012. The results of the Olomouc I pilot study were presented by Dr Miloš Táborský from the University Hospital Olomouc.
› Verified 4 days ago
Dr. Chester R. Smialowicz, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 200 Trenton Rd, Browns Mills, NJ 08015 Phone: 609-677-1046 Fax: 609-677-1306 | |
Evan Matthew Nevel, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 200 Trenton Road, Browns Mills, NJ 08015 Phone: 609-893-6611 | |
Sena Sumathisena, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Trenton Rd, Browns Mills, NJ 08015 Phone: 609-893-1200 Fax: 609-735-0175 | |
Stephen Justin Szawlewicz, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Trenton Road, Browns Mills, NJ 08015 Phone: 609-893-6611 Fax: 609-893-6038 | |
Batool Razvi, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 130 Lakehurst Rd, Browns Mills, NJ 08015 Phone: 609-893-3133 | |
Dr. Benjamin A Rosen, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 200 Trenton Rd, Browns Mills, NJ 08015 Phone: 609-893-6611 | |
Allen Mogtader, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 200 Trenton Rd, Browns Mills, NJ 08015 Phone: 609-893-1200 Fax: 609-735-0175 |